HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Fibrinolysis in diabetes mellitus. Role of overweight and hypertriglyceridemia.

Abstract
The variations of dilute blood clot lysis time (DBCLT) in 103 diabetic patients were investigated in terms of insulin dependency, body weight, serum lipids and presence of diabetic vascular diseases. The results showed that DBCLT was significantly longer in the 34 overweight diabetic patients (437 +/- 68 min) than in the 69 diabetics at or below the ideal body weight (240 +/- 28 min) or in the 76 normalipidemic normal weight control subjects (253 +/- 12 min). DBCLT was also longer in the hypertrigliceridemic diabetic patients than in the normolipidemic ones. The mean lysis time was similar in diabetic patients with and without retinopathy. However, a higher level of fibrinolytic inhibitors was found in patients with diabetic small vessel disease. In vitro inhibition of plasma factor XIII by p-chlormercuribenzoate (PCMB) caused an acceleration of DBCLT and the differences between lysis time in the overweight diabetics and in the controls were attenuated. These results suggested that deficient thrombolysis is rather due to overweight and to disturbances of lipid metabolism than to diabets and/or its vascular complications and that enhanced fibrin crosslinking is at least partially responsible for delayed clot lysis.
AuthorsM Cucuianu, T Fekete, C Marcusiu, R Mösler, A Duţu
JournalMedecine interne (Med Interne) 1984 Jul-Sep Vol. 22 Issue 3 Pg. 171-7 ISSN: 0377-1202 [Print] Romania
PMID6494764 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Chloromercuribenzoates
  • Triglycerides
  • p-Chloromercuribenzoic Acid
  • Factor XIII
Topics
  • Adolescent
  • Adult
  • Aged
  • Chloromercuribenzoates (pharmacology)
  • Diabetes Complications
  • Diabetes Mellitus (blood)
  • Diabetes Mellitus, Type 1 (blood, complications)
  • Diabetes Mellitus, Type 2 (blood, complications)
  • Diabetic Angiopathies (blood)
  • Diabetic Retinopathy (blood)
  • Factor XIII (antagonists & inhibitors)
  • Female
  • Fibrinolysis (drug effects)
  • Humans
  • Hyperlipoproteinemias (blood, complications)
  • Male
  • Middle Aged
  • Obesity
  • Triglycerides (blood)
  • p-Chloromercuribenzoic Acid

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: